Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001731122-25-001105
Filing Date
2025-08-12
Accepted
2025-08-12 16:08:20
Documents
48
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q e6751_10-q.htm   iXBRL 10-Q 704942
2 EXHIBIT 31.1 e6751_ex31-1.htm EX-31.1 7915
3 EXHIBIT 31.2 e6751_ex31-2.htm EX-31.2 7915
4 EXHIBIT 32.1 e6751_ex32-1.htm EX-32.1 5856
5 GRAPHIC image_001.jpg GRAPHIC 27513
6 GRAPHIC image_002.jpg GRAPHIC 28496
  Complete submission text file 0001731122-25-001105.txt   3442584

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE avxl-20250630.xsd EX-101.SCH 31936
8 XBRL CALCULATION FILE avxl-20250630_cal.xml EX-101.CAL 26685
9 XBRL DEFINITION FILE avxl-20250630_def.xml EX-101.DEF 85803
10 XBRL LABEL FILE avxl-20250630_lab.xml EX-101.LAB 256694
11 XBRL PRESENTATION FILE avxl-20250630_pre.xml EX-101.PRE 194294
50 EXTRACTED XBRL INSTANCE DOCUMENT e6751_10-q_htm.xml XML 406201
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37606 | Film No.: 251206710
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)